Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (51,771,000)	$ (37,238,000)
Adjustments to reconcile net loss to net cash used in operations:
Net amortization of premiums and discounts on marketable securities	83,000	0
Depreciation and amortization	1,018,000	206,000
Noncash lease expense	2,938,000	0
Stock-based compensation expense	6,702,000	3,051,000
Change in fair value of the Series A redeemable convertible preferred stock tranche liability	0	10,341,000
Changes in assets and liabilities:
Prepaid expenses and other current assets and other assets	527,000	(1,363,000)
Accounts payable	883,000	3,451,000
Accrued compensation	(508,000)	257,000
Accrued research costs	(173,000)	(463,000)
Accrued expenses and other current liabilities and other liabilities	55,000	(86,000)
Operating lease liabilities	(3,088,000)	0
Net cash used in operating activities	(43,334,000)	(21,844,000)
Cash flows from investing activities:
Purchases of property and equipment	(4,658,000)	(1,123,000)
Purchases of investments in marketable securities	(254,225,000)	0
Net cash used in investing activities	(258,883,000)	(1,123,000)
Cash flows from financing activities:
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs	0	165,521,000
Proceeds from initial public offering, net of issuance costs	0	219,454,000
Proceeds from issuance of common stock upon exercise of vested stock options	13,000	21,000
Proceeds from employee stock purchase plan	414,000	0
Proceeds from issuance of common stock upon early exercises of stock options	0	268,000
Repurchase of unvested early exercised shares	(15,000)	0
Net cash provided by financing activities	412,000	385,264,000
Net increase in cash, cash equivalents and restricted cash	(301,805,000)	362,297,000
Cash, cash equivalents and restricted cash, at beginning of period	378,692,000	19,817,000
Cash, cash equivalents and restricted cash, at end of period	76,887,000	382,114,000
Reconciliation of cash, cash equivalents and restricted cash to statement of financial position:
Cash and cash equivalents	75,171,000	381,965,000
Restricted cash	1,716,000	149,000
Cash, cash equivalents and restricted cash in statement of financial position	76,887,000	382,114,000
Supplemental disclosures of non-cash investing and financing information:
Conversion of redeemable convertible preferred stock to common stock at closing of initial public offering	0	260,532,000
Purchases of property and equipment included in accounts payable	(395,000)	0
Offering costs included in accrued expenses	0	1,277,000
Vesting of early exercised stock options	$ 96,000	$ 49,000